This week, I had an insightful conversation with David Sans, PhD, FAARM, MBA, who heads healthcare investment banking at EF Hutton. We discussed the intricacies of different Public Offering strategies, including micro IPOs, which offer a unique avenue for biotech companies. David provides a deep perspective on the strategic implications of IPOs for biotech funding. He emphasized the importance of investor support and strategic banking partnerships, especially for micro IPOs. We also discussed the potential of AI in reshaping financial services and the future of outcome-based pricing models in investment. David's personal insights reveal the demanding yet rewarding nature of investment banking and highlight crucial aspects to consider for those pursuing a career in this field.
Connect with us!
Link In with Carina
Subscribe here:
Learn more about Recruitomics Consulting
Check out our reading list
Download our free startup resources guide to grow your biotech efficiently
If you're on the job market, visit the Collaboratory Career Hub
00:00 Introduction to Biotech and Investment Banking
00:48 David Sands' Background and Career Journey
02:12 Transition from Biotech to Finance
04:53 Understanding Micro IPOs
06:37 Challenges and Strategies in Biotech IPOs
16:38 The Role of the FDA in Biotech IPOs
18:30 Understanding IPO Disparities
18:42 Key Factors for a Successful IPO
19:29 Aftermarket Support and Investor Relations
20:59 The Role of Long-Term Investors
21:34 Personal Investment Strategies
22:29 Innovations in Financial Services
24:40 Challenges for Biotech CEOs
26:32 Career Path in Investment Banking
28:50 Future of Financial Services and AI
33:37 Book Recommendations and Closing Thoughts
